Dirk Schadendorf
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, Brase J, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt H, Dick J, Engel D, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke J, Klose J, Fendler W, Thommen D, Helfrich I, Schadendorf D, Roesch A. Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer 2023; 4:1395.
Sep 1, 2023Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Sep 1, 2023Nat Cancer 2023; 4:1395
Váraljai Renáta, Zimmer Lisa, Al-Matary Yahya, Kaptein Paulien, Albrecht Lea J, Shannan Batool, Brase Jan C, Gusenleitner Daniel, Amaral Teresa, Wyss Nina, Utikal Jochen, Flatz Lukas, Rambow Florian, Reinhardt Hans Christian, Dick Jenny, Engel Daniel R, Horn Susanne, Ugurel Selma, Sondermann Wiebke, Livingstone Elisabeth, Sucker Antje, Paschen Annette, Zhao Fang, Placke Jan M, Klose Jasmin M, Fendler Wolfgang Peter, Thommen Daniela S, Helfrich Iris, Schadendorf Dirk, Roesch Alexander
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, Brase J, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt H, Dick J, Engel D, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke J, Klose J, Fendler W, Thommen D, Helfrich I, Schadendorf D, Roesch A. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer 2023; 4:1292-1308.
Jul 31, 2023Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Jul 31, 2023Nat Cancer 2023; 4:1292-1308
Váraljai Renáta, Zimmer Lisa, Al-Matary Yahya, Kaptein Paulien, Albrecht Lea J, Shannan Batool, Brase Jan C, Gusenleitner Daniel, Amaral Teresa, Wyss Nina, Utikal Jochen, Flatz Lukas, Rambow Florian, Reinhardt Hans Christian, Dick Jenny, Engel Daniel R, Horn Susanne, Ugurel Selma, Sondermann Wiebke, Livingstone Elisabeth, Sucker Antje, Paschen Annette, Zhao Fang, Placke Jan M, Klose Jasmin M, Fendler Wolfgang Peter, Thommen Daniela S, Helfrich Iris, Schadendorf Dirk, Roesch Alexander
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Garbe C, Keim U, Amaral T, Berking C, Eigentler T, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis C, Ascierto P, Eggermont A, Grob J, Hauschild A, Sekulovic L, Long G, Luke J, Michielin O, Peris K, Schadendorf D, Kirkwood J, Lorigan P, Central Malignant Melanoma Registry (CMMR). Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol 2022; 40:3741-3749.
Jun 16, 2022Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Jun 16, 2022J Clin Oncol 2022; 40:3741-3749
Garbe Claus, Keim Ulrike, Amaral Teresa, Berking Carola, Eigentler Thomas Kurt, Flatz Lukas, Gesierich Anja, Leiter Ulrike, Stadler Rudolf, Sunderkötter Cord, Tüting Thomas, Utikal Jochen, Wollina Uwe, Zimmer Lisa, Zouboulis Christos C, Ascierto Paolo Antonio, Eggermont Alexander M M, Grob Jean-Jacques, Hauschild Axel, Sekulovic Lidija Kandolf, Long Georgina V, Luke Jason J, Michielin Olivier, Peris Ketty, Schadendorf Dirk, Kirkwood John M, Lorigan Paul C, Central Malignant Melanoma Registry (CMMR)
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
Wagner N, Utikal J, Umansky V, Garbe C, Schadendorf D, Holland-Letz T, Herpel E, Sucker A, Lichtenberger R, Funder A, Kehrel C, Kemper C, Schuermans V, Tarnanidis K, Reith M, Gries M, Weide B, Gebhardt C. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J Immunother Cancer 2019; 7:343.
Dec 5, 2019Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
Dec 5, 2019J Immunother Cancer 2019; 7:343
Wagner Nikolaus, Utikal Jochen, Umansky Viktor, Garbe Claus, Schadendorf Dirk, Holland-Letz Tim, Herpel Esther, Sucker Antje, Lichtenberger Ramtin, Funder Anne, Kehrel Coretta, Kemper Charlotte, Schuermans Valerie, Tarnanidis Kathrin, Reith Maike, Gries Mirko, Weide Benjamin, Gebhardt Christoffer
Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression
Kalkavan H, Rathbun J, Cannon P, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang P, Drexler I, von Laer D, Wollmann G, Sharma P, Kasper S, Helfrich I, Pandyra A, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle P, Lang K. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun 2017; 8:14447.
Mar 1, 2017Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression
Mar 1, 2017Nat Commun 2017; 8:14447
Kalkavan Halime, Rathbun Jessica, Cannon Paula M, Scheu Stefanie, Bauer Jens, Chauhan Jagat, Häussinger Dieter, Willimsky Gerald, Löhning Max, Schadendorf Dirk, Brandau Sven, Schuler Martin, Lang Philipp A, Drexler Ingo, von Laer Dorothee, Wollmann Guido, Sharma Piyush, Kasper Stefan, Helfrich Iris, Pandyra Aleksandra A, Gassa Asmae, Virchow Isabel, Flatz Lukas, Brandenburg Tim, Namineni Sukumar, Heikenwalder Mathias, Höchst Bastian, Knolle Percy A, Lang Karl S
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Klein C, Keller U, Goldinger S, Loquai C, Robert C, Kaehler K, Berking C, Bergmann T, Bockmeyer C, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Heinzerling L. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PloS one 2013; 8:e53745.
Jan 14, 2013The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Jan 14, 2013PloS one 2013; 8:e53745
Voskens Caroline J, Mateus Christine, Mohr Peter, Paetzold Sylvie, Satzger Imke, Schadendorf Dirk, Schlaeppi Marc, Schuler Gerold, Schuler-Thurner Beatrice, Trefzer Uwe, Ulrich Jens, Vaubel Julia, von Moos Roger, Weder Patrik, Wilhelm Tabea, Göppner Daniela, Dummer Reinhard, Klein Christina, Keller Ullrich, Goldinger Simone M, Loquai Carmen, Robert Caroline, Kaehler Katharina C, Berking Carola, Bergmann Tanja, Bockmeyer Clemens L, Eigentler Thomas, Fluck Michael, Garbe Claus, Gutzmer Ralf, Grabbe Stephan, Hauschild Axel, Hein Rüdiger, Hundorfean Gheorghe, Justich Armin, Heinzerling Lucie M